Press Materials

Celon Pharma S.A. launches public offering of D-series shares

On 01 July 2021 Celon Pharma S.A. received the decision on approval of the prospectus by the Polish Financial Supervision Authority and published its prospectus in connection with its public offering of D-series shares (the “Offering”). The maximum price in the Offering was set at PLN 45 per share. The Company intends to issue up to 6,000,000 shares and obtain EUR 60 million to finance development of its clinical pipeline and for other corporate purposes, over the course of the next two years.

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes.

Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes. This double-blind, randomized, placebo-controlled, multiple dose Phase II study will evaluate the ability of orally administered CPL’280 to control blood glucose in patients with diagnosed type 2 diabetes. Both naiveRead more »

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.

Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more »

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting.  In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »